Trovagene Inc., of San Diego, said it reached an agreement with Poc Capital LLC, to fund clinical development of onvansertib, its first-in-class, third-generation oral and highly selective Polo-like kinase 1 inhibitor in a phase Ib/II trial in patients with metastatic colorectal cancer.